{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:38:42Z","timestamp":1793799522047,"version":"4.6.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40265-020-01257-4","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T07:02:57Z","timestamp":1579676577000},"page":"285-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":130,"title":["Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent"],"prefix":"10.1007","volume":"80","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenine","family":"Esquivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Zelenitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney K.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denice","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe R. S.","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Joseph P.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"1257_CR1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.2011.06354.x","volume":"1241","author":"ML Nelson","year":"2011","unstructured":"Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci. 2011;1241:17\u201332.","journal-title":"Ann N Y Acad Sci"},{"key":"1257_CR2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00018-009-0172-6","volume":"67","author":"M Thaker","year":"2010","unstructured":"Thaker M, Spanogiannopoulos P, Wright GD. The tetracycline resistome. Cell Mol Life Sci. 2010;67:419\u201331.","journal-title":"Cell Mol Life Sci"},{"key":"1257_CR3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","volume":"64","author":"GG Zhanel","year":"2004","unstructured":"Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines. Drugs. 2004;64:63\u201388.","journal-title":"Drugs"},{"key":"1257_CR4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/AAC.01066-13","volume":"58","author":"MP Draper","year":"2014","unstructured":"Draper MP, Weir S, Macone A, Donatelli J, Trieber CA, Tanaka SK, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014;58:1279\u201383.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR5","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","volume":"24","author":"SK Tanaka","year":"2016","unstructured":"Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016;24:6409\u201319.","journal-title":"Bioorg Med Chem"},{"key":"1257_CR6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/acsinfecdis.8b00349","volume":"5","author":"JL Markley","year":"2019","unstructured":"Markley JL, Fang L, Gasparrini AJ, Symister CT, Kumar H, Tolia NH, et al. Semisynthetic analogues of anhydrotetracycline as inhibitors of tetracycline destructase enzymes. ACS Infect Dis. 2019;5:618\u201333.","journal-title":"ACS Infect Dis"},{"key":"1257_CR7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/CMR.00002-11","volume":"24","author":"BM Marshall","year":"2011","unstructured":"Marshall BM, Levy SB. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev. 2011;24:718\u201333.","journal-title":"Clin Microbiol Rev"},{"key":"1257_CR8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/antibiotics5040032","volume":"5","author":"C Heidrich","year":"2016","unstructured":"Heidrich C, Mitova S, Schedlbauer A, Connell S, Fucini P, Steenbergen J, et al. The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome. Antibiotics. 2016;5:32.","journal-title":"Antibiotics"},{"key":"1257_CR9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","volume":"65","author":"I Chopra","year":"2001","unstructured":"Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65:232\u201360.","journal-title":"Microbiol Mol Biol Rev"},{"key":"1257_CR10","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1128\/AAC.01536-15","volume":"59","author":"L Honeyman","year":"2015","unstructured":"Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, et al. Structure\u2013activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother. 2015;59:7044\u201353.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR11","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","volume":"58","author":"AB Macone","year":"2014","unstructured":"Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58:1127\u201335.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76:567\u201388.","journal-title":"Drugs"},{"key":"1257_CR13","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use NUZYRA TM safely and effectively. See full prescribing information for NUZYRA. NUZYRA (omadacycline) for injection, for intravenous use NUZYRA (omadacycline) tablets, for oral use. http:\/\/www.fda.gov\/medwatch."},{"key":"1257_CR14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/cid\/ciz394","volume":"69","author":"JC Gallagher","year":"2019","unstructured":"Gallagher JC. Omadacycline: a modernized tetracycline. Clin Infect Dis. 2019;69:S1\u20135.","journal-title":"Clin Infect Dis"},{"key":"1257_CR15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/cid\/ciz242","volume":"69","author":"RR Watkins","year":"2019","unstructured":"Watkins RR, Deresinski S. Omadacycline: a novel tetracycline derivative with oral and intravenous formulations. Clin Infect Dis. 2019;69:890\u20136.","journal-title":"Clin Infect Dis"},{"key":"1257_CR16","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/cid\/ciz395","volume":"69","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Steenbergen J, Zhanel GG. Microbiology and preclinical review of omadacycline. Clin Infect Dis. 2019;69:S6\u201315.","journal-title":"Clin Infect Dis"},{"key":"1257_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","volume":"19","author":"MD Huband","year":"2019","unstructured":"Huband MD, Pfaller MA, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY antimicrobial surveillance programme, 2017. J Glob Antimicrob Resist. 2019;19:56\u201363.","journal-title":"J Glob Antimicrob Resist"},{"key":"1257_CR18","first-page":"269","volume-title":"Tetracyclines and tetracycline derivatives. Comprehensive Biotechnology","author":"ML Nelson","year":"2011","unstructured":"Nelson ML, Levy SB. Tetracyclines and tetracycline derivatives. Comprehensive Biotechnology, vol. 3. 2nd ed. Amsterdam: Elsevier; 2011. p. 269\u201383.","edition":"2"},{"key":"1257_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14787210.4.1.9","volume":"4","author":"GG Zhanel","year":"2006","unstructured":"Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther. 2006;4:9\u201325.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1257_CR20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1515\/hsz-2013-0292","volume":"395","author":"F Nguyen","year":"2014","unstructured":"Nguyen F, Starosta AL, Arenz S, Sohmen D, D\u00f6nh\u00f6fer A, Wilson DN. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014;395:559\u201375.","journal-title":"Biol Chem"},{"key":"1257_CR21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/1060028018818094","volume":"53","author":"JA Dougherty","year":"2019","unstructured":"Dougherty JA, Sucher AJ, Chahine EB, Shihadeh KC. Omadacycline: a new tetracycline antibiotic. Ann Pharmacother. 2019;53:486\u2013500.","journal-title":"Ann Pharmacother"},{"key":"1257_CR22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.femsle.2005.02.034","volume":"245","author":"MC Roberts","year":"2005","unstructured":"Roberts MC. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett. 2005;245:195\u2013203.","journal-title":"FEMS Microbiol Lett"},{"key":"1257_CR23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/ph12020063","volume":"12","author":"Sousa Dur\u00e3es","year":"2019","unstructured":"Dur\u00e3es Sousa. Omadacycline: a newly approved antibacterial from the class of tetracyclines. Pharmaceuticals. 2019;12:63.","journal-title":"Pharmaceuticals"},{"key":"1257_CR24","doi-asserted-by":"crossref","unstructured":"Mendes R, Castanheira M, Armstrong E, Steenbergen J, Flamm R. Omadacycline in vitro activity against a molecularly characterized collection of clinical isolates with known tetracycline resistance mechanisms [abstract no 1377 plus poster]. Infectious Disease Week; 3\u20137 Oct 2018; San Francisco.","DOI":"10.1093\/ofid\/ofy210.1208"},{"key":"1257_CR25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","volume":"11","author":"S Villano","year":"2016","unstructured":"Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421\u201334.","journal-title":"Future Microbiol"},{"key":"1257_CR26","unstructured":"Dubois J, Dubois M, Steenbergen JN. In vitro activity of omadacycline against resistant Staphylococcus aureus [abstract no P1829 plus poster]. In: 28th European Congress and Clinical Microbiology and Infectious Disease; 21\u201324 April 2018; Madrid."},{"key":"1257_CR27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2017.10.010","volume":"90","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Rhomberg PR, Huband MD, Flamm RK. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Diagn Microbiol Infect Dis. 2018;90:143\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1257_CR28","doi-asserted-by":"crossref","first-page":"e02411\u201316","DOI":"10.1128\/AAC.02411-16","volume":"61","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Rhomberg PR, Huband MD, Flamm RK. Activities of omadacycline and comparator agents against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe. Antimicrob Agents Chemother. 2017;61:e02411\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR29","doi-asserted-by":"crossref","first-page":"e00018\u201317","DOI":"10.1128\/AAC.00018-17","volume":"61","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Huband MD, Rhomberg PR, Flamm RK. Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010\u20132011. Antimicrob Agents Chemother. 2017;61:e00018\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR30","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ijantimicag.2018.01.006","volume":"51","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). Int J Antimicrob Agents. 2018;51:848\u201353.","journal-title":"Int J Antimicrob Agents"},{"key":"1257_CR31","unstructured":"Zhanel GG, Baxter A, Hink R, Liang N, Lagac\u00e9-Wiens PRS, Hoban DJ, et al. In vitro antimicrobial activity of omadacycline, a new aminomethylcycline, against Gram-positive and Gram-negative bacterial pathogens isolated from patients attending Canadian hospitals in 2015: The CANWARD Study [abstract no Saturday-46 plus poster]. American Society for Microbiology; 1\u20135 June 2017; Louisiana."},{"key":"1257_CR32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jinf.2010.03.024","volume":"60","author":"DJ Farrell","year":"2010","unstructured":"Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect. 2010;60:440\u201351.","journal-title":"J Infect"},{"key":"1257_CR33","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/ofid\/ofy263","volume":"6","author":"HS Sader","year":"2019","unstructured":"Sader HS, Mendes RE, Le J, Denys G, Flamm RK, Jones RN. Antimicrobial susceptibility of Streptococcus pneumoniae for North America, Europe, Latin America, and the Asia-Pasific Region: results from 20\u00a0years of the SENTRY antimicrobial surveillance program (1997\u20132016). Open Forum Infect Dis. 2019;6:S14\u201323.","journal-title":"Open Forum Infect Dis"},{"key":"1257_CR34","doi-asserted-by":"crossref","unstructured":"Horn K, Gotfried MH, Steenbergen JN, Villano SA, Tzanis E, Garrity-Ryan L, et al. Comparison of omadacycline (OMC) and tigecycline (TGC) pharmacodynamics (PD) in the plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) in healthy subjects [abstract no OS1018 plus poster]. In: 27th European Congress of Clinical Microbiology and Infectious Disease; 22\u201325 April 2017; Vienna.","DOI":"10.1128\/AAC.01135-17"},{"key":"1257_CR35","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1086\/431672","volume":"41","author":"GA Noskin","year":"2005","unstructured":"Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis. 2005;41:S303\u201314.","journal-title":"Clin Infect Dis"},{"key":"1257_CR36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2010.08.023","volume":"69","author":"LH Bopp","year":"2011","unstructured":"Bopp LH, Baltch AL, Ritz WJ, Michelsen PB, Smith RP. Activities of tigecycline and comparators against Legionella pneumophila and Legionella micdadei extracellularly and in human monocyte-derived macrophages. Diagn Microbiol Infect Dis. 2011;69:86\u201393.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1257_CR37","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.2165\/0003495-200868180-00008","volume":"68","author":"K McKeage","year":"2008","unstructured":"McKeage K, Keating GM. Tigecycline: in community-acquired pneumonia. Drugs. 2008;68:2633\u201344.","journal-title":"Drugs"},{"key":"1257_CR38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.diagmicrobio.2016.10.022","volume":"87","author":"H Lee","year":"2017","unstructured":"Lee H, Kim H, Hee Seo Y, Yong D, Hoon Jeong S, Lee K, et al. In vitro activity of tigecycline alone and antimicrobial combinations against clinical Neisseria gonorrhoeae isolates. Diagn Microbiol Infect Dis. 2017;87:160\u20132.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1257_CR39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jac\/dki197","volume":"56","author":"C Betriu","year":"2005","unstructured":"Betriu C, Culebras E, G\u00f3mez M, Rodr\u00edguez-Avial I, Picazo JJ. In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother. 2005;56:349\u201352.","journal-title":"J Antimicrob Chemother"},{"key":"1257_CR40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1179\/joc.2005.17.Supplement-1.5","volume":"17","author":"D Felmingham","year":"2005","unstructured":"Felmingham D. Tigecycline\u2014the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline. J Chemother. 2005;17:5\u201311.","journal-title":"J Chemother"},{"key":"1257_CR41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/dkm213","volume":"60","author":"VA Luna","year":"2007","unstructured":"Luna VA, King DS, Gulledge J, Cannons AC, Amuso PT, Cattani J. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre(R) automated microbroth dilution and Etest(R) agar gradient diffusion methods. J Antimicrob Chemother. 2007;60:555\u201367.","journal-title":"J Antimicrob Chemother"},{"key":"1257_CR42","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/1060028019850173","volume":"53","author":"M Heaney","year":"2019","unstructured":"Heaney M, Mahoney MV, Gallagher JC. Eravacycline: the tetracyclines strike back. Ann Pharmacother. 2019;53:1124\u201335.","journal-title":"Ann Pharmacother"},{"key":"1257_CR43","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1128\/AAC.40.1.212","volume":"40","author":"L Welsh","year":"1996","unstructured":"Welsh L, Gaydos C, Quinn TC. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob Agents Chemother. 1996;40:212\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR44","doi-asserted-by":"crossref","first-page":"e00047\u201318","DOI":"10.1128\/AAC.00047-18","volume":"62","author":"L Stapert","year":"2018","unstructured":"Stapert L, Wolfe C, Shinabarger D, Marra A, Pillar C. In vitro activities of omadacycline and comparators against anaerobic bacteria. Antimicrob Agents Chemother. 2018;62:e00047\u2013+.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR45","doi-asserted-by":"crossref","first-page":"e02522\u201318","DOI":"10.1128\/AAC.02522-18","volume":"63","author":"C Shoen","year":"2019","unstructured":"Shoen C, Benaroch D, Sklaney M, Cynamon M, Benaroch D, Cynamon M. In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2019;63:e02522\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR46","doi-asserted-by":"crossref","first-page":"e02551\u201317","DOI":"10.1128\/AAC.02551-17","volume":"62","author":"EJC Goldstein","year":"2018","unstructured":"Goldstein EJC, Citron DM, Tyrrell KL, Leoncio E, Merriama CV. Comparative in vitro activity of omadacycline against dog and cat bite wound isolates. Antimicrob Agents Chemother. 2018;62:e02551\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR47","doi-asserted-by":"crossref","first-page":"e02434\u201316","DOI":"10.1128\/AAC.02434-16","volume":"61","author":"J Steenbergen","year":"2017","unstructured":"Steenbergen J, Tanaka SK, Miller LL, Halasohoris SA, Hershfield JR. In vitro and in vivo activity of omadacycline against two biothreat pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017;61:e02434\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR48","unstructured":"Kohlhoff SA, Huerta N, Hammerschlag MR. In vitro activity of omadacycline against Chlamydia pneumoniae [abstract no Saturday-626 plus poster]. American Society for Microbiology; 7\u201311 June 2018; Atlanta."},{"key":"1257_CR49","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1128\/AAC.01734-16","volume":"60","author":"KB Waites","year":"2016","unstructured":"Waites KB, Crabb DM, Liu Y, Duffy LB. In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human Mycoplasmas and Ureaplasmas. Antimicrob Agents Chemother. 2016;60:7502\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR50","unstructured":"Flamm RK, Steenbergen JN, Huband MD, Rhomberg PR, Sader HS. Activity of omadacycline when tested against respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus isolated during 2016 from medical centers in the USA [abstract no A6856 plus poster]. American Thoracic Society; 19\u201324 May 2017; Washington."},{"key":"1257_CR51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00007691-198206000-00001","volume":"4","author":"BA Cunha","year":"1982","unstructured":"Cunha BA, Sibley CM, Ristuccia AM. Doxyxycline. Ther Drug Monit. 1982;4:115\u201335.","journal-title":"Ther Drug Monit"},{"key":"1257_CR52","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1201\/9781498747967","volume-title":"Minocycline Kucers\u2019 the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs","author":"M Lindsay Grayson","year":"2017","unstructured":"Lindsay Grayson M. Minocycline Kucers\u2019 the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs, vol. 1. 7th ed. Washington: American Society for Microbiology; 2017. p. 1230\u201348.","edition":"7"},{"key":"1257_CR53","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijantimicag.2009.06.021","volume":"34","author":"E Bishburg","year":"2009","unstructured":"Bishburg E, Bishburg K. Minocycline\u2014an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents. 2009;34:395\u2013401.","journal-title":"Int J Antimicrob Agents"},{"key":"1257_CR54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.diagmicrobio.2017.05.004","volume":"88","author":"A Chen","year":"2017","unstructured":"Chen A, Smith KP, Whitfield BA, Zucchi PC, Lasco TM, Bias TE, et al. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline. Diagn Microbiol Infect Dis. 2017;88:365\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1257_CR55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jiph.2009.10.001","volume":"3","author":"W Jamal","year":"2010","unstructured":"Jamal W, Rotimi VO, Pal T, Sonnevend A, Dimitrov TS. Comparative in vitro activity of tigecycline and other antimicrobial agents against Shigella species from Kuwait and the United Arab of Emirates. J Infect Public Health. 2010;3:35\u201342.","journal-title":"J Infect Public Health"},{"key":"1257_CR56","doi-asserted-by":"crossref","first-page":"e00470\u201319","DOI":"10.1128\/AAC.00470-19","volume":"63","author":"A Kaushik","year":"2019","unstructured":"Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL. In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63:e00470\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR57","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/13543784.2014.965253","volume":"23","author":"M Bassetti","year":"2014","unstructured":"Bassetti M, Righi E. Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs. 2014;23:1575\u201384.","journal-title":"Expert Opin Investig Drugs"},{"key":"1257_CR58","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","volume":"74","author":"HI Bax","year":"2019","unstructured":"Bax HI, de Vogel CP, Mouton JW, de Steenwinkel JEM. Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus. J Antimicrob Chemother. 2019;74:2930\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"1257_CR59","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1749-6632.2011.06323.x","volume":"1241","author":"JA Sutcliffe","year":"2011","unstructured":"Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011;1241:122\u201352.","journal-title":"Ann N Y Acad Sci"},{"key":"1257_CR60","unstructured":"Diehl D, Bionda N, Cady NC, Strickland A, Tanaka SK. In vitro activity of omadacycline against Escherichia coli biofilms [abstract no Monday-552 plus poster]. American Society for Microbiology; 16\u201320 June 2016; Boston."},{"key":"1257_CR61","doi-asserted-by":"crossref","unstructured":"Kim O, Leahy RG, Traczewski M, MAocne A, Steenbergen JN. Activity and efficacy of omadacycline against Clostridium difficile [abstract no P1325 plus poster]. In: 26th European Congress of Clinical Microbiology and Infectious Disease; 9\u201312 April 2016; Amsterdam.","DOI":"10.26226\/morressier.56d6be7ad462b80296c97dee"},{"key":"1257_CR62","doi-asserted-by":"crossref","unstructured":"Dubois J, Dubois M, Martel F, Tanaka SK. In vitro activity of omadacycline against Legionella pneumophilia [abstract no Monday-551 plus poster). American Society for Microbiology; 16\u201320 June 2016; Boston.","DOI":"10.26226\/morressier.56d6be7ad462b80296c97ddc"},{"key":"1257_CR63","unstructured":"Sweeney D, Hall D, D. S, Pillar C. Activity of omadacycline against clinical isolates of Neisseria gonorrhea including ciprofloxacin-resistant isolates [abstract no Monday-001 plus poster]. American Society for Microbiology; 16\u201320 June 2016; Boston."},{"key":"1257_CR64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2018.11.010","volume":"94","author":"AC Fluit","year":"2019","unstructured":"Fluit AC, van Gorkum S, Vlooswijk J. Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants. Diagn Microbiol Infect Dis. 2019;94:78\u201380.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1257_CR65","doi-asserted-by":"crossref","first-page":"e02262\u201318","DOI":"10.1128\/AAC.02262-18","volume":"63","author":"CG Carvalhaes","year":"2019","unstructured":"Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS. Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and Taiwan: results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016). Antimicrob Agents Chemother. 2019;63:e02262\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR66","doi-asserted-by":"crossref","first-page":"e02327\u201317","DOI":"10.1128\/AAC.02327-17","volume":"62","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as PART of the 2016 SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2018;62:e02327\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR67","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/j.1742-1241.2006.01188.x","volume":"60","author":"ML Townsend","year":"2006","unstructured":"Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract. 2006;60:1662\u201372.","journal-title":"Int J Clin Pract"},{"key":"1257_CR68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diagmicrobio.2018.01.019","volume":"91","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Rhomberg PR, Huband MD, Flamm RK. Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). Diagn Microbiol Infect Dis. 2018;91:179\u201383.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1257_CR69","doi-asserted-by":"crossref","first-page":"737","DOI":"10.5301\/ijao.5000027","volume":"34","author":"JB Kaplan","year":"2011","unstructured":"Kaplan JB. Antibiotic-induced biofilm formation. Int J Artif Organs. 2011;34:737\u201351.","journal-title":"Int J Artif Organs"},{"key":"1257_CR70","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1128\/AAC.01393-16","volume":"60","author":"H Sun","year":"2016","unstructured":"Sun H, Ting L, Machineni S, Praestgaard J, Kuemmell A, Stein DS, et al. Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects. Antimicrob Agents Chemother. 2016;60:7431\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jcph.814","volume":"57","author":"E Tzanis","year":"2017","unstructured":"Tzanis E, Manley A, Villano S, Tanaka SK, Bai S, Loh E. Effect of food on the bioavailability of omadacycline in healthy participants. J Clin Pharmacol. 2017;57:321\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1257_CR72","doi-asserted-by":"crossref","first-page":"e01487\u201317","DOI":"10.1128\/AAC.01487-17","volume":"62","author":"LA Bundrant","year":"2018","unstructured":"Bundrant LA, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, et al. Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens. Antimicrob Agents Chemother. 2018;62:e01487\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR73","doi-asserted-by":"crossref","first-page":"e02083\u201318","DOI":"10.1128\/AAC.02083-18","volume":"63","author":"JS Overcash","year":"2019","unstructured":"Overcash JS, Bhiwandi P, Garrity-Ryan L, Steenbergen J, Bai S, Chitra S, et al. Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: results from a phase 1 study. Antimicrob Agents Chemother. 2019;63:e02083\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR74","unstructured":"Sun H, Ting L, Maietta R, Machineni S, Praestgaard J, Kuemmell A, et al. A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulation of PTK 0796 in healthy subjects [abstract no P1423 plus poster]. In: 22nd European Congress of Clinical Microbiology and Infectious Disease; 31 Mar\u20133 April 2012; London."},{"key":"1257_CR75","doi-asserted-by":"crossref","first-page":"e02057\u201317","DOI":"10.1128\/AAC.02057-17","volume":"62","author":"JK Berg","year":"2018","unstructured":"Berg JK, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, et al. Pharmacokinetics and safety of omadacycline in subjects with impaired renal function. Antimicrob Agents Chemother. 2018;62:e02057\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR76","doi-asserted-by":"crossref","first-page":"e01135\u201317","DOI":"10.1128\/AAC.01135-17","volume":"61","author":"MH Gotfried","year":"2017","unstructured":"Gotfried MH, Horn K, Garrity-Ryan L, Villano S, Tzanis E, Chitra S, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother. 2017;61:e01135\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR77","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","volume":"47","author":"J Flarakos","year":"2017","unstructured":"Flarakos J, Du Y, Gu H, Wang L, Einolf HJ, Chun DY, et al. Clinical disposition, metabolism and in vitro drug\u2013drug interaction properties of omadacycline. Xenobiotica. 2017;47:682\u201396.","journal-title":"Xenobiotica"},{"key":"1257_CR78","doi-asserted-by":"crossref","first-page":"e01784\u201316","DOI":"10.1128\/AAC.01784-16","volume":"61","author":"W Lin","year":"2017","unstructured":"Lin W, Flarakos J, Du Y, Hu W, He H, Mangold J, et al. Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats. Antimicrob Agents Chemother. 2017;61:e01784\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR79","unstructured":"Lakota E, Van Wart S, Tzanis E, Bhavnani S, Ambrose P, Rubino C. Population pharmacokinetic (PK) analyses of omadacycline using phase 1 and phase 3 data [abstract no. Saturday-628 plus poster]. American Society for Microbiology; 7\u201311 June 2018; Atlanta."},{"key":"1257_CR80","unstructured":"Lakota E, Steenbergen J, McGovern O, Tzanis E, Bhavnani S, Rubino C. Omadacycline pharmacokinetics: impact of comorbidities [abstract no P1943 plus poster]. 29th European Congress Clinical Microbiology and Infectious Disease; 13\u201316 April 2019; Amsterdam."},{"key":"1257_CR81","unstructured":"Ting L, Kovacs SJ, Praestgaard J, Maietta R, Stein DS, Sunkara G, et al. Pharmacokinetics of omadacycline (PTK0796) in subjects with hepatic impairment [abstract no A-1282 plus poster]. In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9\u201312 Sept 2012; San Francisco."},{"key":"1257_CR82","doi-asserted-by":"crossref","first-page":"e00624\u201319","DOI":"10.1128\/AAC.00624-19","volume":"63","author":"AJ Lepak","year":"2019","unstructured":"Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamics of omadacycline against Staphylococcus aureus in the neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2019;63:e00624\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR83","doi-asserted-by":"crossref","first-page":"e02368\u201316","DOI":"10.1128\/AAC.02368-16","volume":"61","author":"AJ Lepak","year":"2017","unstructured":"Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model. Antimicrob Agents Chemother. 2017;61:e02368\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR84","unstructured":"Bhavnani S, Hammel J, Lakota E, Liolios K, Rubino C, Steenbergen J, et al. Assessment of pharmacokinetic-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) [abstract no P1944 plus poster]. In: 29th European Congress of Clinical Microbiology and Infectious Disease; 13\u201316 April 2019; Amsterdam."},{"key":"1257_CR85","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/ciz396","volume":"69","author":"FM Abrahamian","year":"2019","unstructured":"Abrahamian FM, Sakoulas G, Tzanis E, Manley A, Steenbergen J, Das AF, et al. Omadacycline for acute bacterial skin and skin structure infections. Clin Infect Dis. 2019;69:S23\u201332.","journal-title":"Clin Infect Dis"},{"key":"1257_CR86","unstructured":"Craig W, Andes DR, Odinecs A. In vivo pharmacodynamics of MK-2764\/PTK 0796 against various Gram-positive and Gram-negative bacteria in the thighs of neutropenic and normal mice [abstrat no F1-1974 plus poster]. In: 46th Interscience Conference on Antiretroviral Agents and Chemotherapy; 27\u201330 Sept 2006; San Francisco."},{"key":"1257_CR87","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1128\/AAC.00948-12","volume":"56","author":"GJ Noel","year":"2012","unstructured":"Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56:5650\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"1257_CR88","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380:528\u201338.","journal-title":"N Engl J Med"},{"issue":"10","key":"1257_CR89","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19(10):1080\u201390.","journal-title":"Lancet Infect Dis"},{"key":"1257_CR90","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517\u201327.","journal-title":"N Engl J Med"},{"key":"1257_CR91","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/ciz397","volume":"69","author":"JA Ramirez","year":"2019","unstructured":"Ramirez JA, Tzanis E, Curran M, Noble R, Chitra S, Manley A, et al. Early clinical response in community-acquired bacterial pneumonia: from clinical endpoint to clinical practice. Clin Infect Dis. 2019;69:S33\u20139.","journal-title":"Clin Infect Dis"},{"key":"1257_CR92","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/cid\/ciz398","volume":"69","author":"S Opal","year":"2019","unstructured":"Opal S, File TM, van der Poll T, Tzanis E, Chitra S, McGovern PC. An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic. Clin Infect Dis. 2019;69:S40\u20137.","journal-title":"Clin Infect Dis"},{"key":"1257_CR93","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/cid\/ciz309","volume":"69","author":"KA Rodvold","year":"2019","unstructured":"Rodvold KA, Pai MP. Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline. Clin Infect Dis. 2019;69:S16\u201322.","journal-title":"Clin Infect Dis"},{"key":"1257_CR94","unstructured":"Lexicomp Online, Interaction Monograph, Tetracyclines\/Antacids [Internet]: Wolters Kluwer Clinical Drug Information, Inc.; 2019. online.lexi.com. Accessed 03 August 94. Lexi. Lexicomp: Iron\/Tet."},{"key":"1257_CR95","unstructured":"Lexicomp Online, Interaction Monograph, Tetracyclines\/Iron Salts [Internet]: Wolters Kluwer Clinical Drug Information, Inc.; 2019. online.lexi.com. Accessed 03 August."},{"key":"1257_CR96","unstructured":"Lexicomp Online, Interaction Monograph, Tetracyclines\/Bismuth Subsalicylate [Internet]: Wolters Kluwer Clinical Drug Information, Inc.; 2019. online.lexi.com. Accessed 03 August."},{"key":"1257_CR97","unstructured":"Lexicomp Online, Interaction Monograph, Vitamin K Antagonists\/Tetracyclines [Internet]: Wolters Kluwer Clinical Drug Information, Inc.; 2019. online.lexi.com. Accessed 03 August."},{"key":"1257_CR98","unstructured":"Lexicomp Online, Interaction Monograph, Tetracyclines\/Digoxin [Internet]: Wolters Kluwer Clinical Drug Information, Inc.; 2019. online.lexi.com. Accessed 03 August."},{"key":"1257_CR99","unstructured":"Lexicomp Online, Interaction Monograph, Penicillin\/Tetracyclines [Internet]: Wolters Kluwer Clinical Drug Information, Inc.; 2019. online.lexi.com. Accessed 03 August."},{"key":"1257_CR100","unstructured":"Lexicomp Online, Interaction Monograph, Estrogen Derivatives (Contraceptive)\/ Tetracyclines [Internet]: Wolters Kluwer Clinical Drug Information, Inc.; 2019. online.lexi.com. Accessed 03 August."},{"key":"1257_CR101","first-page":"429","volume":"10","author":"GG Zhanel","year":"1999","unstructured":"Zhanel GG, Siemens S, Slayter K, Mandell L. Antibiotic and oral contraceptive drug interactions: is there a need for concern? Can J Infect Dis. 1999;10:429\u201333.","journal-title":"Can J Infect Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01257-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01257-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01257-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T06:27:05Z","timestamp":1665556025000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01257-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01257-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"22 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and Ethical Standards"}},{"value":"No conflicts are declared for Jenine Esquivel, Sheryl Zelenitsky, Courtney K. Lawrence, Heather J. Adam, Alyssa Golden, Rachel Hink, Liam Berry, Frank Schweizer, Michael A. Zhanel, Denice Bay, Philippe R. S. Lagac\u00e9-Wiens, Andrew J. Walkty, Joseph P. Lynch III and James A. Karlowsky. Dr Zhanel has received research grants from Paratek Pharmaceuticals (omadacycline), Pfizer (tigecycline), and Tetraphase (eravacycline).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors are grateful to Paratek Pharmaceuticals for their assistance with literature retrieval and an unrestricted research grant to aid in funding Jenine Esquivel.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}